No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
www.aartipharmalabs.comNo one on the platform currently holds AARTIPHARM.NS.
No tracked institution reports a position in AARTIPHARM.NS as of their last filing.
No one on the platform has traded AARTIPHARM.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 7.8% | 9.9% | — | — | — | |
| Rev. Growth % | -14.0% | |||||
| Profit Margin % | 9.6% | 10.9% | ||||
| Free Cash Flow Margin % | -10.2% | -4.3% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $20.6B | — | $17.80 | $17.80–$17.80 | — | 1 |
| 2028 | $23.7B | +14.8% | $25.50 | $25.50–$25.50 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| AARTIPHARM.NSAarti Pharmalabs Limited | $789.45 | -4.53% | $71.6B | — |
| FDC.BOFDC Limited | $349.35 | +2.15% | $56.8B | — |
| FDC.NSFDC Limited | $349.65 | +2.40% | $56.9B | — |
| KOVAI.BOKovai Medical Center and Hospital Limited | $6014.60 | -3.29% | $65.8B | — |
| MARKSANS.BOMarksans Pharma Limited | $312.40 | -4.84% | $141.6B | — |
| MARKSANS.NSMarksans Pharma Limited | $312.85 | -5.02% | $141.8B | — |
| SHILPAMED.NSShilpa Medicare Limited | $911.90 | -5.12% | $178.4B | — |
Source: Financial Modeling Prep · peers by sector/industry